Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Core Insights - Shattuck Labs, Inc. is participating in the 24th Annual Needham Virtual Healthcare Conference from April 7–10, 2025, with a presentation scheduled for April 9, 2025, at 3:00 PM EDT [1][2] Company Overview - Shattuck Labs, Inc. is a biotechnology company focused on developing novel therapeutics for inflammatory and immune-related diseases, with a lead program SL-325 targeting the DR3/TL1A pathway [4] - The company has expertise in protein engineering and aims to create first-in-class treatments for conditions such as inflammatory bowel disease (IBD) [4] Product Development - SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody, showing high affinity binding and superior activity compared to TL1A antibodies, with an IND filing expected in Q3 2025 [3]